Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 293 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Herpes Simplex Virus Clear all
Completed Not applicable Interventional Accepts healthy volunteers

An Investigation Into the Efficacy of Herpecin L at Reducing the Frequency and Severity of Cold Sores

NCT05796635
View directory record Official record
Conditions
Cold Sores
Interventions
Herpecin L
Other
Lead sponsor
Focus Consumer Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 11, 2026, 5:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

HSV Seroprevalence and Diagnosis of Genital Herpes in Pregnant Women

NCT00291044
View directory record Official record
Conditions
Pregnancy
Interventions
testing for HSV 1 and 2 IgG type specific antibosy
Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2010 · Synced Oct 11, 2026, 5:00 AM EDT
Completed Phase 1 Interventional

Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes Caused by HSV-2

NCT00274300
View directory record Official record
Conditions
HSV-2
Interventions
pPJV7630 administered by PMED
Biological
Lead sponsor
PowderMed
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2007 · Synced Oct 11, 2026, 5:00 AM EDT
Completed Early Phase 1 Interventional

3VM1001 Cream for the Treatment of Pain Associated With Post Herpetic Neuralgia (PHN)

NCT03421613
View directory record Official record
Conditions
Treatment of PHN
Interventions
3VM1001, Placebo
Drug · Other
Lead sponsor
CDA Research Group, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 11, 2026, 5:00 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes

NCT01658826
View directory record Official record
Conditions
Genital Herpes
Interventions
AIC316, Valacyclovir
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Indianapolis, Indiana • Portland, Oregon • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 11, 2026, 5:00 AM EDT
Completed Phase 1 Interventional

Gene Transfer for Cancer Pain

NCT00804076
View directory record Official record
Conditions
Cancer Pain
Interventions
NP2
Biological
Lead sponsor
Diamyd Inc
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
5
States / cities
Miami, Florida • New Orleans, Louisiana • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced Oct 11, 2026, 5:00 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy

NCT07227285
View directory record Official record
Conditions
Urinary Bladder, Overactive, Spinal Cord Injury
Interventions
Urodynamics, EG110A, Patient-reported Outcome
Other · Drug
Lead sponsor
Cyllene Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Downey, California • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 11, 2026, 5:00 AM EDT
Completed Phase 3 Interventional

A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV

NCT00002358
View directory record Official record
Conditions
HIV Infections, Chickenpox
Interventions
Sorivudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Wallingford, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 2, 2007 · Synced Oct 11, 2026, 5:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Potential Influence of Esomeprazole on the Pharmacokinetics of Pritelivir

NCT05513625
View directory record Official record
Conditions
HSV Infection
Interventions
Pritelivir, ESO and pritelivir
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 11, 2026, 5:00 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

NCT05966090
View directory record Official record
Conditions
Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine, HZ/su vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
11
States / cities
Daphne, Alabama • Tempe, Arizona • Corte Madera, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 11, 2026, 5:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2

NCT01112956
View directory record Official record
Conditions
Genital Herpes
Interventions
Not listed
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
16 Years to 55 Years
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Oct 11, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

NCT01687595
View directory record Official record
Conditions
Herpes Simplex Type 2
Interventions
HerpV and QS-21, Placebo
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Portland, Oregon • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 11, 2026, 5:00 AM EDT
Recruiting No phase listed Observational

The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise

NCT01011712
View directory record Official record
Conditions
EBV, HSV, VZV, HPV, CMV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 100 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 11, 2026, 5:00 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)

NCT01610765
View directory record Official record
Conditions
Herpes Simplex Virus
Interventions
Novel Antiviral Drug, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 98 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Oct 11, 2026, 5:00 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

NCT05683457
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
mRNA-1647, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • St Louis, Missouri • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 11, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy

NCT00851786
View directory record Official record
Conditions
Herpes Zoster, HIV Infections
Interventions
ZOSTAVAX, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
43
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 11, 2026, 5:00 AM EDT
Completed Phase 1 Interventional

ZOSTAVAX® in Renal Transplant Patients

NCT01137669
View directory record Official record
Conditions
Herpes Zoster
Interventions
Live attenuated herpes zoster vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 11, 2026, 5:00 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

A 48 Week Observational Study of the Frequency of Symptomatic Herpes Virus I and II in HIV Infected Subjects

NCT05823779
View directory record Official record
Conditions
HIV Disease, Herpes Simplex 1, Herpes Simplex 2
Interventions
Blood draw
Other
Lead sponsor
Global Research Institute
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 11, 2026, 5:00 AM EDT
Completed Phase 4 Interventional Results available

Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

NCT01346475
View directory record Official record
Conditions
Genital Herpes
Interventions
Valacyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 11, 2026, 5:00 AM EDT
Active, not recruiting No phase listed Observational

Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions

NCT05811754
View directory record Official record
Conditions
Herpes Zoster
Interventions
Data collection
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
2,844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Canton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 11, 2026, 5:00 AM EDT
Completed Phase 1 Interventional

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

NCT01017185
View directory record Official record
Conditions
Refractory Head and Neck Cancer, Squamous Cell Carcinoma, Skin, Carcinoma of the Breast, Malignant Melanoma
Interventions
HF10
Drug
Lead sponsor
Takara Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
The Bronx, New York • Portland, Oregon • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 11, 2026, 5:00 AM EDT
Completed Phase 2Phase 3 Interventional

NGX-4010 for the Treatment of Postherpetic Neuralgia

NCT00061776
View directory record Official record
Conditions
Herpes Zoster, Neuralgia, Pain, Peripheral Nervous System Diseases, Shingles
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
28
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2008 · Synced Oct 11, 2026, 5:00 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Herpevac Neonatal Substudy

NCT00138320
View directory record Official record
Conditions
Herpes Simplex
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 30 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
5
States / cities
Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 11, 2026, 5:00 AM EDT